About
Advancing Breast Cancer Precision Medicine
Core Pillars of the Heng Lab
- Multimodal Research: We integrate wet-lab, computational biology, and translational strategies to address clinically important problems that cannot be solved within a single field.
- A Global Network: We partner with world-class physicians and scientists across Harvard, USA, and international institutions.
- Equitable Medicine: Pioneering critical research in transgender cancer to ensure precision medicine serves all populations.
Recent Publications
- The miR-362-3p/BCLAF1 axis regulates cisplatin sensitivity and metastatic progression in triple-negative breast cancer
- MicroRNA spatial profiling for assessing drug efficacy in BRCA1-related triple-negative breast tumors
- Genomic and Transcriptomic Landscape and Determinants of Response of BRCA-related Breast Cancers Treated with Neoadjuvant Chemotherapy (TBCRC 031)
- Associations of stromal markers’ expression in benign breast tissue with subsequent breast cancer risk.
- Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER+ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast Cancer
- Simultaneous Inhibition of PARP/AKT to Intercept Nascent BRCA1/2mut Breast Tumors
